Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments.
Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise.
The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).
Recognising the exciting potential of ADCs, Pheon has built a world class leadership team focused on transitioning its lead asset into clinical development. In parallel, it is developing and building a proprietary pipeline of follow-on ADCs to address the unmet medical need of novel targets in hard-to-treat solid tumors across multiple cancer types.